Balipodect

Overview

Balipodect (TAK-063) is a selective, brain-penetrant and orally active PDE10A inhibitor with an IC 50 of 0.30 nM. Balipodect shows >15000-fold selectivity over other PDEs. Balipodect elevates striatal cAMP and cGMP levels in mice. Balipodect can be used for the study of schizophrenia [1] .

Application

Products | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Phosphodiesterase (PDE)

Product Information

• Catalog No.: HY-12472
• CAS No.: 1238697-26-1
• Molecular Formula: C23H17FN6O2
• Molecular Weight: 428.42
• Purity: 99.47%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.84 mM); Clear solution
• Availability: In-stock

Source

Original product source